

1 Title: Pooling of samples for SARS-CoV-2 surveillance using a rapid antigen test

2

3 Authors: Nol Salcedo¹, Alexander Harmon¹, Bobby Brooke Herrera^{1,2‡}

4

5 Affiliations:

6 ¹E25Bio, Inc., Cambridge, MA, USA

7 ²Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public
8 Health, Boston, MA, USA

9

10 ‡Corresponding Author: BBH, bbherrera@e25bio.com

11

12 Key Words: SARS-CoV-2, COVID-19, rapid antigen test, pooled testing

13

14 Running Title: Pooled testing for SARS-CoV-2 antigen tests

15

16

17

18

19

20

21

22

23

24

25

26

27 Abstract

28

29 While molecular assays, such as RT-PCR, have been widely used throughout the
30 COVID-19 pandemic, the technique is costly and resource intensive. As a means to reduce
31 costs and increase diagnostic efficiency, pooled testing for RT-PCR has been implemented.
32 However, pooling samples for antigen testing has not been evaluated. We propose a pooling
33 strategy for antigen testing that would significantly expand SARS-CoV-2 surveillance, especially
34 for low-to-middle income countries, schools, and workplaces. Our data demonstrate that
35 combining of up to 20 nasal swab specimens per pool can expand surveillance with antigen
36 tests, even if a pool contains only one positive sample.

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53 Introduction

54

55 With ongoing worldwide transmission of severe acute respiratory syndrome coronavirus
56 2 (SARS-CoV-2) and emergent variants, laboratory testing has played an important role in
57 detecting the virus in symptomatic and asymptomatic individuals . Molecular assays, such as
58 reverse-transcription polymerase chain reaction (RT-PCR), are accurate but costly and resource
59 and supply chain intensive, challenging large scale surveillance efforts, especially for low-to-
60 middle income countries. The financial and logistical barriers associated with RT-PCR restricts
61 the ability to rapidly identify and quarantine infected individuals and hinder our ability to estimate
62 community prevalence and epidemic trajectory. These limitations underscore the need for novel
63 and dynamic approaches to individual diagnostics, community surveillance, and epidemic
64 control.

65 Pooling subsamples and processing them in groups by RT-PCR has been proposed as
66 a testing strategy to reduce costs and increase efficiency . If a pool tests negative by RT-PCR,
67 then all of the constituent samples are assumed negative. If a pool tests positive by RT-PCR,
68 then the constituent samples are putatively positive and must be re-tested individually or in mini
69 pools. A recent study demonstrated that a range of positive pools could be identified, even if the
70 Ct value of a single sample was up to 34 . Simple RT-PCR pooling designs can also be used to
71 assess prevalence without individual specimen identification, by using quantitative viral load
72 measurements in each positive pool, where the viral load measurement from a pool is
73 proportional to the sum of the diluted viral loads from each positive sample in the pool .

74 Public health surveillance tools, such as rapid antigen tests, have also been advocated
75 for since early in the pandemic to help control SARS-CoV-2 spread. Rapid antigen tests are
76 optimized to detect the presence of SARS-CoV-2 proteins in individuals during the acute,
77 infectious phase of COVID-19, and can be self-administered or performed at the point-of-care,
78 leading to faster results from the time of sampling and more frequent testing . However, pooled

79 testing using rapid antigen tests, has not been evaluated. In this study, we examined a pooling
80 strategy for public health surveillance of SARS-CoV-2 using a rapid antigen test.

81

82 Methods

83

84 Clinical Dilution Panel

85

86 The study included a clinical dilution panel provided by the non-profit PATH
87 (www.path.org). The panel was prepared from human nasal swab eluate discards in phosphate-
88 buffered saline. Swab eluates positive for SARS-CoV-2 by RT-PCR from multiple individuals
89 were combined and diluted into nasal swab eluate pools from individuals testing negative for
90 SARS-CoV-2 by RT-PCR. Dilutions were then aliquoted and frozen at -80°C.

91 The primary studies under which the samples were collected received ethical clearance
92 from PATH Institutional Review Board (IRB) (approval number 00004244). All excess samples
93 and corresponding data were banked and de-identified prior to analysis. This study received an
94 exemption determination from the PATH IRB.

95

96 Quantitative Reverse-Transcriptase Polymerase Chain Reaction

97

98 Aliquots from the clinical dilution panel were thawed and 200 µl was used for extraction
99 with the QIAamp Viral RNA Mini Kit (Qiagen, Germany). Nucleic acids were eluted in 50 µl and
100 10 µl were used for qRT-PCR using the CDC's 2019-nCoV Real-Time RT-PCR N1 assay on the
101 QuantStudio 5 Real-Time PCR System (Applied Biosystems, Foster City, CA). Viral loads were
102 determined by measuring the concentration of the RNA using a previously qualified standard to
103 determine genomic RNA levels.

104

105 Sample Pooling

106

107 For the 20-fold pooled sample testing, 50 μ l from a single RT-PCR confirmed positive
108 nasal swab specimen dilution was mixed with 50 μ l from nineteen RT-PCR confirmed negative
109 nasal swab specimens. The total volume of each pool was 1 ml. For the non-pooled testing, the
110 RT-PCR confirmed nasal swab specimen dilutions were not mixed with any negative nasal
111 swab specimens, and were tested directly on the rapid antigen test. For pooled and single
112 sample testing, 100 μ l of the sample was applied to the COVID-19 rapid antigen test and
113 allowed to react for 15 minutes before test result image capture.

114

115 COVID-19 Antigen Test

116

117 The rapid antigen test (E25Bio, Inc., Cambridge, MA) contains a monoclonal antibody
118 and a nanoparticle conjugate that detects the nucleocapsid protein of SARS-CoV-2. Interaction
119 of the immobilized Test and Control line antibodies with antigen and the nanoparticle conjugate
120 produces visible bands, indicating whether the test is positive or negative. The lot used in this
121 study was validated using recombinant SARS-CoV-2 nucleocapsid protein (SinoBiological,
122 China) from 0.1 ng/ml to 500 ng/ml in a total volume of Solution Buffer (E25Bio, Inc.,
123 Cambridge, MA) of 100 μ l (data not shown).

124

125 Image Analysis

126

127 Rapid antigen test result images were captured via the iPhone E25Bio Passport
128 application (currently only available via TestFlight) and analyzed using image processing
129 software, Image J (NIH), to machine-read and quantify test results. The average pixel intensity
130 was quantified at the Test line, Control line, and background areas. The background-adjusted

131 Test line signal was then normalized to the background-subtracted Control line and expressed
132 as an arbitrary unit (A.U.).

133

134 Results

135

136 To analyze the effect of sample pooling on the analytical sensitivity of a rapid antigen
137 test, we compared antigen detectability of single RT-PCR confirmed nasal swab specimens with
138 varying Ct values versus when pooled into 19 RT-PCR confirmed negative nasal swab
139 specimens. Antigen detectability was determined by applying to a rapid antigen test 100 μ l of a
140 single RT-PCR positive nasal swab specimen or 100 μ l of a pooled sample. Each pooled
141 sample consisted of 50 μ l of a RT-PCR positive nasal swab dilution specimen and a 950 μ l
142 negative nasal swab mixture (50 μ l from 19 RT-PCR confirmed negative nasal swab
143 specimens).

144 Our results show that the rapid antigen test detected positive pools between Ct values
145 18.3 (VL: 7.6E7) and 30.1 (VL: 4.8E4), compared to 18.3 and 31.9 (VL: 3.5E4) for single nasal
146 swab specimens (Fig. 1). These data suggest that combining of up to 20 samples per pool can
147 expand surveillance with rapid antigen tests, even if a pool contains only one positive sample.
148 Only in the case of a positive pool test result is additional rapid antigen testing and/or RT-PCR
149 of individual samples or smaller pools required.

150

151 Discussion

152

153 We propose a pooling strategy for antigen testing that is easy to implement and can
154 further expand SARS-CoV-2 surveillance. In general, for single sample testing, a nasal swab is
155 collected from an individual, resuspended into 0.5-1 ml solution (e.g. viral transport media,
156 saline solution, antigen test kit buffer solution, etc.), and 100 μ l of the nasal swab specimen is

157 then applied to a rapid antigen test. However, performing individual antigen testing on a single
158 nasal swab specimen can present further cost and logistical limitations when the frequency of
159 antigen testing is increased, especially for wide-scale surveillance. For pooled sample testing,
160 nasal swabs are collected from up to 20 individuals, each of the nasal swabs are then
161 resuspended into 0.3-0.5 ml solution, and 50 μ l from each nasal swab specimen is pooled into a
162 mixture before applying 100 μ l to a rapid antigen test (Fig. 2). If a pool tests negative by an
163 antigen test, then all of the constituent nasal swab specimens are assumed negative. If a pool
164 tests positive by the antigen test, then the constituent nasal swab specimens are putatively
165 positive and should be re-tested in mini pools. If a mini pool remains positive, then antigen
166 testing on individual nasal swab specimens can be performed.

167 Pooled testing using rapid antigen tests is a cost-effective and public health conscious
168 approach to expanding SARS-CoV-2 surveillance, thus further enabling societal reopening,
169 especially in instances where capacity and resources are constrained. Our results show that the
170 rapid antigen test can detect SARS-CoV-2 positive nasal swab specimens up to Ct value 30.1,
171 even when the positive specimen is combined with 19 negative nasal swab specimens.

172 While our experiments suggest that a pooling strategy for antigen testing may be
173 beneficial for SARS-CoV-2 surveillance and identification of individuals during the infectious
174 phase of COVID-19, there are limitations. Specimens collected and tested beyond the acute
175 infection phase (7 days post-infection) will likely escape detection by a rapid antigen test,
176 regardless if the specimen is pooled or non-pooled prior to testing. Enhancing efficiency at the
177 expense of sensitivity must be appropriately considered depending on the purpose of testing
178 and resources available. A number of modeling and clinical studies have shown that increasing
179 the frequency of antigen testing to a minimum of two times per week can increase the
180 performance metrics of an antigen test. Furthermore, pooling adds complexity because
181 samples must be archived, or individuals would need to undergo additional swabbing for
182 potential re-testing.

183 We have shown that a simple design for antigen testing using a sample pooling strategy
184 is straightforward and can enhance SARS-CoV-2 surveillance. Future studies will be important
185 to determine whether pooling strategies can be applied to COVID-19 antibody detection in sera
186 using rapid tests or for antigen detection from other microorganisms. While there are other costs
187 and logistical limitations associated with pooling that we do not consider here, our study
188 highlights the use of antigen tests as a public health tool to help combat the COVID-19
189 pandemic.

190

191 Competing Interests

192

193 NS, AH, and BBH are employed by E25Bio, Inc., a biotechnology company that develops
194 diagnostic assays for fever-causing infectious diseases. This research received no specific
195 grant from any funding agency in the public, commercial, or not-for-profit sectors.

196

197 References

- 198 Cleary, Brian, James A. Hay, Brendan Blumenstiel, Maegan Harden, Michelle Cipicchio, Jon
199 Bezney, Brooke Simonton, *et al.* "Using Viral Load and Epidemic Dynamics to Optimize
200 Pooled Testing in Resource Constrained Settings." *medRxiv* (2021):
201 2020.05.01.20086801. <https://doi.org/10.1101/2020.05.01.20086801>.
202 <https://www.medrxiv.org/content/medrxiv/early/2021/01/15/2020.05.01.20086801.full.pdf>.
- 203 Larremore, D. B., B. Wilder, E. Lester, S. Shehata, J. M. Burke, J. A. Hay, M. Tambe, M. J.
204 Mina, and R. Parker. "Test Sensitivity Is Secondary to Frequency and Turnaround Time
205 for Covid-19 Screening." *Sci Adv* (Nov 20 2020).
206 <https://doi.org/10.1126/sciadv.abd5393>.
207 <https://www.ncbi.nlm.nih.gov/pubmed/33219112>.

- 208 Lauring, A. S., and E. B. Hodcroft. "Genetic Variants of Sars-Cov-2-What Do They Mean?".
209 *JAMA* 325, no. 6 (Feb 9 2021): 529-31. <https://doi.org/10.1001/jama.2020.27124>.
210 <https://www.ncbi.nlm.nih.gov/pubmed/33404586>.
- 211 Lohse, S., T. Pfuhl, B. Berko-Gottel, J. Rissland, T. Geissler, B. Gartner, S. L. Becker, S.
212 Schneitler, and S. Smola. "Pooling of Samples for Testing for Sars-Cov-2 in
213 Asymptomatic People." *Lancet Infect Dis* 20, no. 11 (Nov 2020): 1231-32.
214 [https://doi.org/10.1016/S1473-3099\(20\)30362-5](https://doi.org/10.1016/S1473-3099(20)30362-5).
215 <https://www.ncbi.nlm.nih.gov/pubmed/32530425>.
- 216 Mahmoud, S. A., E. Ibrahim, B. Thakre, J. G. Teddy, P. Raheja, S. Ganesan, and W. A. Zaher.
217 "Evaluation of Pooling of Samples for Testing Sars-Cov- 2 for Mass Screening of Covid-
218 19." *BMC Infect Dis* 21, no. 1 (Apr 17 2021): 360. [https://doi.org/10.1186/s12879-021-](https://doi.org/10.1186/s12879-021-06061-3)
219 [06061-3](https://doi.org/10.1186/s12879-021-06061-3). <https://www.ncbi.nlm.nih.gov/pubmed/33865325>.
- 220 Nash, Beatrice, Anthony Badea, Ankita Reddy, Miguel Bosch, Nol Salcedo, Adam R. Gomez,
221 Alice Versiani, *et al.* "Validating and Modeling the Impact of High-Frequency Rapid
222 Antigen Screening on Covid-19 Spread and Outcomes." *medRxiv* (2021):
223 2020.09.01.20184713. <https://doi.org/10.1101/2020.09.01.20184713>.
224 <https://www.medrxiv.org/content/medrxiv/early/2021/01/30/2020.09.01.20184713.full.pdf>.
- 225 Peeling, R. W., P. L. Olliaro, D. I. Boeras, and N. Fongwen. "Scaling up Covid-19 Rapid Antigen
226 Tests: Promises and Challenges." *Lancet Infect Dis* (Feb 23 2021).
227 [https://doi.org/10.1016/S1473-3099\(21\)00048-7](https://doi.org/10.1016/S1473-3099(21)00048-7).
228 <https://www.ncbi.nlm.nih.gov/pubmed/33636148>.
- 229 Tromberg, B. J., T. A. Schwetz, E. J. Perez-Stable, R. J. Hodes, R. P. Woychik, R. A. Bright, R.
230 L. Fleurence, and F. S. Collins. "Rapid Scaling up of Covid-19 Diagnostic Testing in the
231 United States - the Nih Radx Initiative." *N Engl J Med* 383, no. 11 (Sep 10 2020): 1071-
232 77. <https://doi.org/10.1056/NEJMSr2022263>.
233 <https://www.ncbi.nlm.nih.gov/pubmed/32706958>.

234 Wiersinga, W. J., A. Rhodes, A. C. Cheng, S. J. Peacock, and H. C. Prescott. "Pathophysiology,
235 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (Covid-19): A
236 Review." *JAMA* 324, no. 8 (Aug 25 2020): 782-93.

237 <https://doi.org/10.1001/jama.2020.12839>.

238 <https://www.ncbi.nlm.nih.gov/pubmed/32648899>.

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256


257

258

259


260
261
262
263
264
265

Figures



266
267
268
269
270
271
272
273
274
275
276
277
278

Fig. 1. Analytical sensitivity of a rapid antigen test using single nasal swab specimens versus when pooled. 50 μ l of the positive nasal swab specimens with Ct values ranging between 18.3 and 40 were spiked into 50 μ l of RT-PCR confirmed negative nasal swab specimens from 19 individuals. 100 μ l of the 1 ml pooled samples or 100 μ l of the single positive nasal swab specimens were applied to the rapid antigen test and allowed to react for 15 minutes before test results were image captured. To determine relative nucleocapsid antigen levels detected by the antigen test, images were analyzed using image processing software and reported as an arbitrary unit (A.U.). Ct, cycle threshold. Horizontal dashed line, limit of detection for the rapid antigen test.



279

280

281 **Fig. 2. Sample pooling strategy for antigen testing.** A) Nasal swab specimens are collected,

282 where 50 μ l from each individual is pooled into a single mixture and 100 μ l is then applied to the

283 rapid test. If a pool tests negative by the antigen test, then all of the constituent nasal swab

284 specimens are assumed negative. B) If a pool tests positive by the antigen test, then the

285 constituent nasal swab specimens are putatively positive and should be re-tested in mini pools.

286 If a mini pool remains positive, then antigen testing on individual nasal swab specimens can be

287 performed.

288